Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Credit agrmnt [a]
Director departure
Inv. presentation
Quarterly results
Acq. announced
|
|
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/19/2019 |
GN
| Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management |
| 11/13/2018 |
GN
| Detailed Research: Economic Perspectives on Pernix Therapeutics, Hallador Energy, Vince Holding, Tuesday Morning, Information Services Group, and Sienna Biopharmaceuticals — What Drives Growth in Today's Competitive Landscape |
| 11/02/2018 |
GN
| Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8 |
| 09/12/2018 |
GN
| Pernix Therapeutics Holdings, Inc.'s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek® |
| 08/27/2018 |
GN
| Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek® |
| 08/09/2018 |
GN
| Pernix Therapeutics Reports Second Quarter 2018 Financial Results |
| 08/01/2018 |
GN
| Pernix Therapeutics Announces a Series of Transactions to Strengthen Its Balance Sheet and Improve Financial Flexibility |
| 07/31/2018 |
GN
| Pernix Therapeutics to Report Second Quarter 2018 Financial Results on Thursday, August 9 |
| 06/22/2018 |
GN
| Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss |
| 05/10/2018 |
GN
| Pernix Therapeutics Reports First Quarter 2018 Financial Results |
| 04/23/2018 |
GN
| Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss |
| 03/27/2018 |
GN
| Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg |
| 02/16/2018 |
GN
| Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company's Subsidiary, Macoven Pharmaceuticals |
| 02/06/2018 |
GN
| Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion |
| 01/05/2018 |
GN
| Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor® |
| 11/06/2017 |
GN
| Pernix Therapeutics Announces Sale of Non-Core Product |
| 10/17/2017 |
GN
| Pernix Therapeutics Announces Planned Departure of Chief Financial Officer |
| 07/20/2017 |
GN
| Pernix Commences Refinancing Transactions to Fortify Balance Sheet |
| 07/20/2017 |
GN
| Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results |
| 06/28/2017 |
GN
| Pernix Therapeutics Added to Russell Microcap® Index |
| 05/15/2017 |
GN
| Pernix Therapeutics Reports First Quarter 2017 Financial Results and Provides Business Update |
| 05/01/2017 |
GN
| Pernix Therapeutics Provides Update on Availability of Zohydro® ER with BeadTek™ 20mg Strength |
| 03/28/2017 |
GN
| Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results |
| 02/03/2017 |
GN
| Pernix Therapeutics Provides Update on Arbitration |
|
|